Future Cardia™ Insertable Cardiac Monitor in Subjects With Paroxysmal Atrial Fibrillation (First-in-Human Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a first-in-human, prospective, multi-center, pre-market single-arm clinical trial to evaluate the Future Cardia™ ICM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients

NCT00708786

Sleep Apnoea

COMPLETED PHASE4

AI Powered Mapping Technology for Identifying Arrhythmias

NCT06939478

Arrhythmias, Cardiac

RECRUITING

Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG

NCT00273195

Ventricular Arrhythmias

COMPLETED NA

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

NCT00673842

Myocardial Infarction Sudden Death

COMPLETED PHASE3

Non-Invasive 3D Mapping for Identifying Origin and Preferential Propagation of Ventricular Arrhythmias

NCT03831516

Premature Ventricular Complex Ventricular Arrythmia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this first-in-human, prospective, multi-center, pre-market single-arm clinical investigation is to evaluate the safety and performance of the Future Cardia™ ICM by assessing the insertion procedure, sensing and detection performance and data monitoring transmission success, and device- or procedure-related complication rates over a 6-month follow-up period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arrhythmias, Cardiac Atrial Fibrillation Bradycardia Ventricular Tachycardia Asystole

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Insertable Cardiac Monitor Implant.

Group Type EXPERIMENTAL

Future Cardia™ Insertable Cardiac Monitoring (ICM) System

Intervention Type DEVICE

The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Future Cardia™ Insertable Cardiac Monitoring (ICM) System

The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients (≥18 years old and \<75 years old)
2. Paroxysmal AF, defined as AF that terminates spontaneously or with intervention within 7 days of onset (ESC 2020 guidelines). In order to be included, patients must present one of the following conditions:

1. paroxysmal AF patients that are candidates for AF ablation;
2. patients hospitalized for symptomatic AF, who failed to convert in the emergency room (ER):
3. outpatients who require treatment with anti-arrhythmic drugs (AAD) (mostly propafenone or flecainide; more rarely sotalol or amiodaron are given for PAF).
3. Patient is willing and able to provide written informed consent.
4. Patient is willing and able to comply with the protocol, including follow-up visits and data transmissions.

Exclusion Criteria

1. Patient who is scheduled to have MRI or is likely to require MR screening. The Future Cardia implant is not compatible with MRI.
2. Currently indicated for or implanted with a cardiovascular implantable electronic device (CIED) (e.g., ICM or ILR, pacemaker, ICD, CRT-D or CRT-P device) or hemodynamic monitoring system.
3. Compromised immune system or at high risk of developing an infection.
4. Active systemic infection or history of any infection within the last 30 days.
5. Subjects who are female must:

1. have a negative pregnancy test by β-hCG blood test.
2. not breastfeeding
3. either be surgically sterile, postmenopausal (cessation of menses for at least 1 year), or if they have childbearing potential, agree to use a medically accepted, highly effective method of contraception during the entire duration of the study.
6. Subject is currently enrolled in another investigational study.
7. Any condition or abnormality (including clinical laboratory, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator, would compromise the efficacy evaluation, safety of the patient, or would interfere with or complicate study procedures or assessments.
8. Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological diagnosis).
9. Obesity, Class 2 (BMI ≥ 35-40) or Class 3 (BMI ≥ 40).
10. Subject is unwilling or unable to comply with the study procedures.
11. Subject is legally incapacitated and unable to provide written informed consent.

12. Patient with abnormal thoracic anatomy or scar tissue at the implant site that may adversely impact the insertion procedure.
13. For patients currently taking warfarin at the time of insertion, most recent INR value (within 7 days) is less than 3.5 for an acceptable risk of bleeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No